Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -193.56%.

  • Foghorn Therapeutics' EBITDA Margin rose 4240.00% to -193.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -295.53%, marking a year-over-year increase of 5317.00%. This contributed to the annual value of -378.99% for FY2024, which is 10007.00% down from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' EBITDA Margin is -193.56%, which was up 18.71% from -238.11% recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year EBITDA Margin high stood at -77.35% for Q3 2023, and its period low was -63,617.07% during Q3 2021.
  • Its 3-year average for EBITDA Margin is -368.26%, with a median of -331.30% in 2024.
  • As far as peak fluctuations go, Foghorn Therapeutics' EBITDA Margin plummeted by 5,335,618bps in 2021, and later skyrocketed by 6,320,339bps in 2022.
  • Over the past 5 years, Foghorn Therapeutics' EBITDA Margin (Quarterly) stood at -4,086.96% in 2021, then surged by 341,755bps to -669.41% in 2022, then soared by 27,005bps to -399.36% in 2023, then slumped by 29,140bps to -690.76% in 2024, then spiked by 4,240bps to -193.56% in 2025.
  • Its EBITDA Margin was -193.56% in Q3 2025, compared to -238.11% in Q2 2025 and -318.46% in Q1 2025.